Communiqués Novartis AG

Actions

NOVN

CH0012005267

Marché Fermé - Swiss Exchange Autres places de cotation 17:30:19 12/06/2024			Varia. 5j.	Varia. 1 janv.
94,66 ^CHF	+0,62%		+2,08%	+11,54%

11/06	NOVARTIS AG : JP Morgan est neutre	ZD
10/06	Bourse Zurich: le SMI à la peine, glisse sous les 12'150 points	AW

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Novartis : Latest analysis of Novartis NATALEE study shows Kisqali® reduces risk of cancer recurrence for early breast cancer patients with high risk node negative disease	31/05	PU
Novartis Scemblix® Phase III data first to show superior efficacy with a favorable safety and tolerability profile vs. standard-of-care TKIs in adults with newly diagnosed CML	31/05	GL
Novartis Phase III data confirm sustained efficacy and long-term safety of oral remibrutinib in chronic spontaneous urticaria	31/05	GL
Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company's IgA nephropathy (IgAN) portfolio	25/05	GL
Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo	25/05	GL
Amgen And Sandoz Settle Denosumab BPCIA Litigation	20/05	AQ
Novartis meets all tender offer conditions to acquire MorphoSys AG for EUR 68 per share in cash	16/05	GL
Novartis highlights pioneering innovation in CML with data from Scemblix® Phase III ASC4FIRST study in newly diagnosed patients at ASCO and EHA	15/05	GL
Novartis receives FDA Breakthrough Therapy designation for Scemblix in 1L CML	13/05	AQ
Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update	10/05	AQ
Novartis : enters agreement to acquire Mariana Oncology, strengthening radioligand therapy pipeline	02/05	PU
Novartis : Q1 2024 impact and sustainability update	30/04	PU
European Commission authorises one of first ustekinumab biosimilars in Europe	26/04	AQ
Novartis and Medicines for Malaria Venture announce positive efficacy and safety data for a novel treatment for babies <5 kg with malaria	24/04	GL
Novartis, Danaher rise; Nucor, Cadence Design Systems fall, Tuesday, 4/23/2024	23/04	AQ
Novartis radioligand therapy Lutathera® FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors	23/04	GL
Novartis: Q1 Earnings Snapshot	23/04	AQ
Novartis, au premier trimestre: croissance à deux chiffres du chiffre d’affaires et expansion de la marge core; hausse des prévisions pour 2024	23/04	GL
Novartis delivers double-digit sales growth and core margin expansion in Q1; FY 2024 guidance raised	23/04	GL
Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment- naïve people with relapsing multiple sclerosis	17/04	GL